#NewGSK

Analysts Meet 17th August 2021





GlaxoSmithKline Pharmaceuticals Limited India

OUR PURPOSE

At GSK, we unite science, talent and technology to get ahead of disease together.

gsl

Globally, we have businesses that research, develop and manufacture pharmaceuticals and vaccines.

OUR STRATEGY



We prevent and treat disease with vaccines, specialty and general medicines.





OUR CULTURE

Ambitious for patients

to deliver what matters better and faster

Accountable for impact

with clear ownership and support to succeed

Do the right thing

with integrity and care because people can count on

OUR PRIORITIES


Innovation

Trust

Performance

GSK India is the 2nd highest contributor to EM and continue to be the growth driver






GSK India's YTD Gr. remains Double Digit keeping EM Gr. Positive



GSK Performance in Indian Pharmaceutical – Acute Markets

Our performance reflected commitment





Business Continuity

>95% Back on Field (By Jun'21)

Digital share of voice at ~ **19Mn touchpoints ,+10% vs** LY, 14% conversation rate through high impact channels Jan'21-Jun'21

- Supply Continuity with an OTIF of 97%
- Line Extension Augmentin ES, Neosporin 10gm
 - High Employee Engagement

We Continue to Lead in our Represented market



Brand Leadership

No #1 in its Represented market

Augmentin, Calpol, Ceftum, T-Bact, Neosporin, Betnovates, Infanrix Hexa, Havrix, Varilrix, Boostrix

Rx Leadership

Therapy Leadership

No #1 in Dermatology, Vaccines self-pay market No #1 in its represented market across key

customers: GP, Pediatrician, Dentist, Dermatologist, ENT

Vaccine Consumer campaigns further accelerated driving awareness & need for vaccination

voot

SYNC

Video platforms



Launched in >10 languages with a clear objective to increase confidence of HCPs, Sales force and Consumers on Vaccination

World Immunization Week Awareness Campaign



Reach: ~2M, Impressions: 10M (24th-30th April 2021),parents aged 25-40yrs



Views: ~22M, Impressions: ~150M (Launched April & continue till year end) Parents of kids aged 0-3 years old.

"Flu Vaccination Awareness campaign"




Reach:80M, TV & Digital Impressions: >1Bn (Launched June 12th, 4 weeks campaign) Parents of 0-5 years old

G


"Hepatitis A awareness campaign- Passport to health"






Nucala access increasing to more eligible severe asthma patients







Source: External IQVIA Jun'21 Dataset

Digitally we remained Up and Running



3 critical success factors to mastering multi-channel HCP engagement to deliver exceptional customer experiences



Financials: 5year Performance



EBITDA	Particulars	Mar 17 YTD	Mar 18 YTD	Mar 19 YTD	Mar 20 YTD	Mar 21 YTD	CAGR % 21-17	CAGR % 20-17
5-YR CAGR	Vaccines Total Vaccines	514 514	478 478	556 629	675 676	762 762	10% 10%	9% 10%
~13%	Сх	213	188	226	243	274	6%	4%
	 Pharma Total Pharma	1,633 2,192	,	,	2,138 2,265	2,096 2,118	6% -1%	
* Vx Brand	Total	2,920	2,820	3,089	3,187	3,160	2%	3%
5-YR CAGR	EBITDA	420	510	631	658	695	13%	16%
~ 9%	EBITDA Margin	14%	18%	2 0 %	21%	22%		
	5-YR CAGR ~13% * Vx Brand 5-YR CAGR	EBITDA 5-YR CAGR ~13% Cx Pharma Total Pharma * Vx Brand 5-YR CAGR EBITDA	EBITDA 5-YR CAGRParticularsYTD Vaccines~13%Vaccines514Cx213Pharma1,633Total Pharma2,192* Vx Brand 5-YR CAGRTotal2,920EBITDA420	EBITDA 5-YR CAGRParticularsYTDYTDVaccines514478Total Vaccines514478Cx213188Pharma1,6331,776Total Pharma2,1922,154* Vx BrandTotal2,9202,8205-YR CAGREBITDA420510	EBITDA Particulars YTD YTD YTD 5-YR CAGR Vaccines 514 478 556 Total Vaccines 514 478 629 Cx 213 188 226 Pharma 1,633 1,776 1,939 Total Pharma 2,192 2,154 2,234 * Vx Brand Total 2,920 2,820 3,089 EBITDA 420 510 631	EBITDA Particulars YTD YTD YTD YTD YTD 5-YR CAGR Vaccines 514 478 556 675 Total Vaccines 514 478 629 676 Cx 213 188 226 243 Pharma 1,633 1,776 1,939 2,138 Total Pharma 2,192 2,154 2,234 2,265 * Vx Brand Total 2,920 2,820 3,089 3,187 EBITDA 420 510 631 658	EBITDA YTD YTD <t< td=""><td>EBITDA YTD <t< td=""></t<></td></t<>	EBITDA YTD YTD <t< td=""></t<>

New GSK



Purpose	We unite science, talent and technology to get ahead of disease together				
	Health impact + Shareholder returns + Thriving people				
Strategy	We prevent and treat disease with vaccines, specialty and general medicines R&D focused on the science of the immune system, human genetics and advanced technologies to impact health at scale We operate responsibly for all our stakeholders				
Culture	With ambition, accountability and responsibility				

New GSK to positively impact the health of >2.5 bn people over 10 years




Estimated patient impact Estimated global impact 1200 **India Dependence High** Vaccines* 1.3bn 1000 unique patients (m) 800 . **Specialty Medicines* 40m** . 600 . Number of 400 **General Medicines** 700m . . . 200 **Global Health**** 1.2bn 0 Africa Asia & Europe Mid East & North South & Latin Arab States Pacific America America

Estimated total impact >2.5bn people over next 10 years, adjusting for category overlap; *Excludes COVID-19 vaccines or treatments; **Global Health includes donations

Investing to drive step-change in growth and business mix





All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. 2021-26 CAGR is for the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are excluded from the above.

India's future remains exciting with bigger growth opportunities, New launches and Innovation



Classic and Established ProductsVaccines ExpansionNew LaunchesKeep winning on our Primary Care and Derma assets supported by strong CTC strategyExpand classic vaccines Launch new assetsApproved and ready to launch		ÍÍ	
	Keep winning on our Primary Care and Derma assets supported by strong CTC	Expand classic vaccines	


Performance Culture | Employee safety & Engagement



Also as part of the **#New GSK**, We made some critical announcements

Y'2021: GSK Asset Sale





Vemgal Asset

Sale to Hetero Pharma

Regulatory approvals underway

Expected conclusion FY21



Thank You

Q&A